Crinetics Pharmaceuticals (CRNX) Projected to Post Quarterly Earnings on Thursday

Key Points

• Crinetics is scheduled to report Q1 2026 results after the market close on Thursday, May 7 at 4:30 PM ET; analysts expect ($1.20) EPS and $8.511M revenue.
• In the prior quarter the company reported ($1.29) EPS, beating estimates, with $6.16M in revenue; shares trade around $38.44 with a market cap of $4.02B and a 12‑month range of $25.83–$57.99.
• Analysts’ consensus is a “Moderate Buy” with an average target of $76.75, but ratings are mixed and insiders sold about 142,380 shares (~$5.57M) last quarter, leaving insiders with roughly 4.6% ownership.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) is projected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.20) per share and revenue of $8.5110 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.29) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.08. The business had revenue of $6.16 million for the quarter, compared to analysts' expectations of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. The business's quarterly revenue was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.88) earnings per share. On average, analysts expect Crinetics Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Trading Up 0.8%

Shares of CRNX opened at $38.44 on Thursday. The stock has a market capitalization of $4.02 billion, a P/E ratio of -7.78 and a beta of 0.30. The firm's fifty day simple moving average is $38.62 and its two-hundred day simple moving average is $43.95. Crinetics Pharmaceuticals has a 12 month low of $25.83 and a 12 month high of $57.99.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen lowered shares of Crinetics Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Morgan Stanley increased their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the company an "overweight" rating in a research report on Tuesday, January 6th. Citizens Jmp raised their price objective on shares of Crinetics Pharmaceuticals from $96.00 to $97.00 and gave the stock a "market outperform" rating in a report on Tuesday. Finally, Lifesci Capital raised shares of Crinetics Pharmaceuticals to a "strong-buy" rating in a report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $76.75.

Insider Activity

In related news, insider Stephen F. Betz sold 10,612 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $396,570.44. Following the transaction, the insider owned 137,101 shares in the company, valued at $5,123,464.37. The trade was a 7.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Coelho Rogerio Vivaldi sold 5,000 shares of the company's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $36.15, for a total transaction of $180,750.00. Following the completion of the sale, the director owned 16,300 shares in the company, valued at approximately $589,245. This trade represents a 23.47% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 142,380 shares of company stock valued at $5,569,475. 4.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC bought a new position in shares of Crinetics Pharmaceuticals in the second quarter worth approximately $30,000. Smartleaf Asset Management LLC lifted its stake in shares of Crinetics Pharmaceuticals by 107.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company's stock worth $30,000 after buying an additional 331 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Crinetics Pharmaceuticals in the second quarter worth approximately $45,000. Parallel Advisors LLC lifted its stake in shares of Crinetics Pharmaceuticals by 34.6% in the fourth quarter. Parallel Advisors LLC now owns 1,225 shares of the company's stock worth $57,000 after buying an additional 315 shares in the last quarter. Finally, Arax Advisory Partners lifted its stake in shares of Crinetics Pharmaceuticals by 131.2% in the fourth quarter. Arax Advisory Partners now owns 1,498 shares of the company's stock worth $70,000 after buying an additional 850 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company's stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.